Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab

Monitoring of biological treatment efficacy for psoriasis is based on clinical evaluation and patient’s quality of life. However, long-term correlation between Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in real life has not been studied in patients treated wit...

Full description

Bibliographic Details
Main Authors:	Jeanette Halskou Hesselvig, Alexander Egeberg, Nikolai Dyrberg Loft, Claus Zachariae, Kristian Kofoed, Lone Skov
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2017-12-01
Series:	Acta Dermato-Venereologica
Subjects:	psoriasis PASI DLQI correlation ustekinumab
Online Access:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2833

Similar Items

Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis
by: Julia-Tatjana Maul, et al.
Published: (2024-03-01)

Body mass index, disease duration and tumor necrosis factor inhibitor history predict reduced ustekinumab response in Chinese psoriasis patients: A real-world study
by: Xue Xu, et al.
Published: (2021-01-01)

Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
by: Sascha Gerdes, et al.
Published: (2020-07-01)

The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis
by: Jenny M. Norlin, et al.
Published: (2023-11-01)

The combined using of ustekinumab and narrow-band phototherapy in treatment of severe psoriasis
by: Kruglova L.S., et al.
Published: (2015-09-01)

Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population
by: Diana Norris, et al.
Published: (2017-11-01)

Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy
by: J. M. Norlin, et al.
Published: (2017-08-01)

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
by: Boni E. Elewski, et al.
Published: (2017-08-01)

Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment
by: Ali Al Raddadi, et al.
Published: (2016-01-01)

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients
by: Teodora-Larisa Timis, et al.
Published: (2023-05-01)

Correlation of Disease Activity and Quality of Life of Patients with Psoriasis after Narrow-band Ultraviolet B Therapy
by: Lyubomir A. Dourmishev, et al.
Published: (2020-03-01)

The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients
by: Michael Abrouk, et al.
Published: (2017-08-01)

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
by: Andrea Chiricozzi, et al.
Published: (2020-07-01)

Application of Dermatology Life Quality Index‐Relevant (DLQI‐R) in patients with moderate‐to‐severe plaque psoriasis treated with tildrakizumab
by: Philip Laws, et al.
Published: (2023-12-01)

Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review
by: de Ruiter CC, et al.
Published: (2022-05-01)

Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
by: Melis Gönülal, et al.
Published: (2023-12-01)

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis
by: Gil Yosipovitch, et al.
Published: (2019-07-01)

Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry
by: Abby S. Van Voorhees, et al.
Published: (2021-11-01)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023-03-01)

Ustekinumab en psoriasis cutánea y artritis psoriásica
by: Javier E. Rosa, et al.
Published: (2015-06-01)

Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study
by: Nikolai Loft, et al.
Published: (2021-01-01)

Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
by: I. V. Rychkova, et al.
Published: (2019-08-01)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)

Clinical Goals and Barriers to Effective Psoriasis Care
by: Bruce E. Strober, et al.
Published: (2018-12-01)

PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis
by: A. A. Kubanov, et al.
Published: (2017-08-01)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
by: Amy J. Petty, BS, et al.
Published: (2020-08-01)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017-09-01)

Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report
by: Artsiom Klimko, et al.
Published: (2024-01-01)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017-03-01)

Correlation of Psoriasis Disability Index and Psoriasis Area and Severity Index: A Study from Afghanistan
by: Aalemi AK, et al.
Published: (2022-04-01)

Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
by: Chiharu Tateishi,, et al.
Published: (2015-07-01)

Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019-04-01)

Effectiveness of resuming ustekinumab therapy in psoriasis patients with metabolic disorders. Clinical experience
by: I. V. Rychkova, et al.
Published: (2019-02-01)

Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis
by: Rosa M. Romero-Jimenez, et al.
Published: (2018-11-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Associations between body mass index and severity of psoriasis
by: Sobhan M, et al.
Published: (2017-11-01)

Pengaruh Suplementasi Vitamin D Terhadap Perubahan Skor Psoriasis Area and Severity Index (PASI) Pada Pasien Psoriasis: Studi Kasus Dengan Pendekatan Berbasis Bukti
by: Anni Rahmawati, et al.
Published: (2024-03-01)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018-10-01)

Effect of Disease Severity on the Quality of Life and Sense of Stigmatization in Psoriatics
by: Kowalewska B, et al.
Published: (2021-02-01)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
by: Rosita Saraceno, et al.
Published: (2013-09-01)